Regeneron Reports Third Quarter 2015 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- Nasdaq drags on Wall St as AI slowdown fears hammer Nvidia, chipmakers
- Global AI stocks fall as industry chiefs call for slowing development
- Trump slams Anthropic CEO over AI slowdown call
- Oil prices soar over 4% to 16-week high after Saudi strikes
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Leerink Partners Reiterated Outperform Following Regeneron's (REGN) 3Q Beat
November 5, 2015 8:07 AM ESTLeerink Partners reiterated an Outperform rating and $664.00 price target on Regeneron Pharma (NASDAQ: REGN) following the company's 3Q earnings report. REGN reported revenues and EPS of $1.14bn and $1.82, respectively, thereby beating consensus estimates of $1.79 and $1.64. REGN tightened its 2015 non-GAAP R&D guidance... More
Regeneron (REGN) Reports Strong Eylea Sales; Cowen Reiterates Market Perform
November 4, 2015 3:55 PM ESTCowen reiterated a Market Perform rating on Regeneron Pharma (NASDAQ: REGN), and raised the price target to $575.00 (from $550.00), following the company's 3Q15 earnings report. Eylea sales of $734MM were well ahead of consensus of $683MM and 2015 guidance was increased again. Adoption... More
Regeneron (REGN) Tops Q3 EPS by 33c
November 4, 2015 6:31 AM ESTRegeneron (NASDAQ: REGN) reported Q3 EPS of $3.47, $0.33 better than the analyst estimate of $3.14. Revenue for the quarter came in at $1.14 billion versus the consensus estimate of $1.05 billion.
EYLEA® (aflibercept) Injection for Intravitreal Injection
In the third quarter of 2015, net sales of EYLEA in the United States... More